NGL Fine-Chem Limited

Equities

NGLFINE

INE887E01022

Pharmaceuticals

Market Closed - Bombay S.E. 06:00:50 2024-04-26 am EDT 5-day change 1st Jan Change
2,639 INR -2.67% Intraday chart for NGL Fine-Chem Limited +3.73% +18.28%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
NGL Fine-Chem Limited Approves the Appointment of Dhananjay Mungale as Independent Director CI
Crisil Keeps NGL Fine-Chem Rating at BBB+; Outlook Stable MT
NGL Fine-Chem Limited Announces Retirement of Milind Shinde as Independent Director, with Effect from March 31, 2024 CI
NGL Fine-Chem Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Transcript : NGL Fine-Chem Limited, Q2 2024 Earnings Call, Nov 20, 2023
NGL Fine-Chem Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Crisil Keeps SME 1 Rating on NGL Fine-Chem MT
Transcript : NGL Fine-Chem Limited, Q4 2023 Earnings Call, May 19, 2023
NGL Fine-Chem Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
NGL Fine-Chem Limited Recommends Final Dividend for the Financial Year Ended on March 31, 2023, Payable on or After September 4, 2023 CI
ICRA Affirms NGL Fine-Chem Rating at BBB+ MT
NGL Fine-Chem Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Crisil Keeps NGL Fine-Chem Rating at BBB+; Lowers Outlook to Stable MT
Transcript : NGL Fine-Chem Limited, Q3 2022 Earnings Call, Nov 17, 2022
NGL Fine-Chem Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Transcript : NGL Fine-Chem Limited, Q1 2023 Earnings Call, Aug 17, 2022
NGL Fine-Chem Limited Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
NGL Fine-Chem Limited Announces Resignation of K.V. Subramanian as Independent Director CI
NGL Fine-Chem Limited Approves Final Dividend for the Financial Year Ended 31 March, 2022 CI
Crisil Keeps SME 1 Rating on NGL Fine-Chem; Shares Fall 5% MT
Transcript : NGL Fine-Chem Limited, Q4 2022 Earnings Call, May 04, 2022
NGL Fine-Chem Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2022 CI
NGL Fine-Chem Limited Recommends Final Dividend for the Financial Year Ended on 31 March 2022 CI
Crisil Affirms NGL Fine-Chem's Rating at BBB+; Outlook Positive MT
Crisil Keeps BBB+ Rating on NGL Fine-Chem; Raises Outlook to Positive MT
Chart NGL Fine-Chem Limited
More charts
NGL Fine-Chem Limited is an India-based company, which is a manufacturer of pharmaceuticals and intermediates for use in veterinary and human health. The Company caters to various global companies to custom manufacture pharmaceuticals. Its products include APIs Animal Health, APIs Human Health, Intermediates and Specialty Chemicals and Finished Dosage Form. The APIs Animal Health products include Homidium Chloride, Nitroxynil, Clorsulon, Parvaquone, Buparvaquone, Isometamidium Chloride Hydrochloride, Toldimfos Sodium, Butaphosphan, Imidocarb Dipropionate, Triclabendazole, Rafoxanide, Diminazene Aceturate, S-Methoprene, Carprofen and others. The APIs Human Health products include Nitazoxanide and Atovaquone. The Intermediates and Specialty Chemicals product includes 1,4,7-Trimethyl-1,4,7-Triazacylononane and N-Ethyl Glucamine. The Finished Dosage Form products include Diminazene Aceturate Granules and Homidium Chloride Tablets. It has manufacturing plants located around Mumbai.
More about the company
  1. Stock Market
  2. Equities
  3. NGLFINE Stock
  4. News NGL Fine-Chem Limited
  5. Crisil Keeps SME 1 Rating on NGL Fine-Chem